LADX Stock Overview
A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.60 |
| 52 Week High | US$3.50 |
| 52 Week Low | US$0.50 |
| Beta | 1.51 |
| 11 Month Change | -66.99% |
| 3 Month Change | -71.15% |
| 1 Year Change | -63.41% |
| 33 Year Change | -98.85% |
| 5 Year Change | -97.60% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LADX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -25.0% | 2.4% | 0.5% |
| 1Y | -63.4% | 15.6% | 30.7% |
Return vs Industry: LADX underperformed the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: LADX underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| LADX volatility | |
|---|---|
| LADX Average Weekly Movement | 26.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LADX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LADX's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 2 | Stephen Snowdy | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent which targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer.
LadRx Corporation Fundamentals Summary
| LADX fundamental statistics | |
|---|---|
| Market cap | US$297.06k |
| Earnings (TTM) | -US$2.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs LADX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LADX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.78m |
| Earnings | -US$2.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LADX perform over the long term?
See historical performance and comparison